Sun Pharma: Global Specialty Pharma Growth Engine

Sun Pharmaceutical Industries remains India’s largest pharma company, with strong exposure to specialty medicines, generics, India formulations and emerging markets. Q1 FY27 results are available on the company’s investor portal, with continued focus on specialty products and global expansion. Latest News: Sun Pharma received approval to manufacture and market semaglutide in Brazil and launched generic semaglutide in South Africa. The company is also progressing on Nidlegy, while shareholders of Organon approved the proposed acquisition, an important strategic development for Sun Pharma. Corporate Action/Catalysts: The Organon transaction, specialty-drug pipeline, semaglutide opportunity and continued US growth provide significant long-term catalysts. The company also completed its 34th AGM on 31 July 2026 and recommended FY26 final dividend. Key risks include US pricing pressure, regulatory scrutiny, acquisition execution and high expectations embedded in valuation.